EBRD, partners acquire Egypt’s Adwia Pharmaceuticals
EBRD commits $75m to support the company’s growth in Egypt
The European Bank for Reconstruction and Development (EBRD) is joining forces with reputable partners to acquire Egypt’s Adwia Pharmaceuticals company to improve the availability and affordability of medicines, using an investment platform with an initial capital commitment of $250m.
The EBRD is committing $75m to support the company’s growth in Egypt, alongside Development Partners International (DPI), a pan-African private equity firm which is committing $75m, and CDC Group, a development finance institution funded by the UK government, with $100m commitment.
Moreover, the investment platform acquired Celon Laboratories, an Indian oncology and critical-care product specialist.
Adwia will benefit from Celon’s know-how in drug development, including for chronic and life-threatening health conditions.